Since 1992, the National Brain Tumor Society has supported brain tumor research by directly funding grants for brain tumor research and by collaborating with other funding organizations, such as the National Cancer Institute (NCI) Specialized Programs of Research Excellence Program (SPORE), the American Association for Cancer Research (AACR), and the American Association of Neurological Surgeons (AANS).
To measure the contribution of our research funding, we recently performed a quantitative analysis of the more than 400 peer-reviewed scientific publications that resulted from our supported brain tumor research studies. In addition, we analyzed the additional indicators we believe also impact the development of new brain tumor treatments. These indicators include therapeutic targets identified; patents awarded on discoveries research that has led to clinical trials. Together, these findings were consolidated in our summary of current research findings.
During the last two decades, we awarded over $26 million across 244 grants in 30 out of the 50 US states, as well as to groups in Canada, Israel, and The Netherlands. States receiving the most funding included California, Massachusetts, North Carolina, New York, Pennsylvania, and Texas, with MD Anderson Cancer Center in Houston receiving the most individual grants (22). Of all the grants, 68% were for adult brain tumor research, and 22% were for pediatric brain tumor research.
Most (59%) went for the study of malignant gliomas—the most dangerous of brain tumors—and the rest were spread out among other tumor types.
Researchers published 5 to 18 research papers per year between 1994 and 2003 based on our funded research. That number climbed to almost 30 in 2004 and peaked at 54 in 2008. Throughout the period, researchers published 409 scientific papers in 161 different journals. These included high-impact journals such as Cancer Cell and Journal of Clinical Oncology.